3.50
+0.18(+5.42%)
Currency In USD
| Previous Close | 3.32 |
| Open | 3.24 |
| Day High | 3.5 |
| Day Low | 3.17 |
| 52-Week High | 3.65 |
| 52-Week Low | 1.41 |
| Volume | 849,271 |
| Average Volume | 931,134 |
| Market Cap | 126.33M |
| PE | -5.74 |
| EPS | -0.61 |
| Moving Average 50 Days | 2.26 |
| Moving Average 200 Days | 1.94 |
| Change | 0.18 |
If you invested $1000 in Gain Therapeutics, Inc. (GANX) since IPO date, it would be worth $286.89 as of December 04, 2025 at a share price of $3.5. Whereas If you bought $1000 worth of Gain Therapeutics, Inc. (GANX) shares 3 years ago, it would be worth $1,063.83 as of December 04, 2025 at a share price of $3.5.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
GlobeNewswire Inc.
Nov 20, 2025 12:00 PM GMT
GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mit
Gain Therapeutics to Present at Neuroscience 2025
GlobeNewswire Inc.
Oct 30, 2025 11:00 AM GMT
BETHESDA, Md., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the
Gain Therapeutics to Attend the 2025 Maxim Growth Summit
GlobeNewswire Inc.
Oct 16, 2025 11:00 AM GMT
BETHESDA, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule the